Acute GVH Disease
9
0
0
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
11.1%
1 terminated out of 9 trials
75.0%
-11.5% vs benchmark
11%
1 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
MTX and Steroid as First-line Therapy for aGVHD
Gut Decontamination In Pediatric Allogeneic Hematopoietic
MTX and Steroid for aGVHD Treatment
Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease
Skin Disease and Pulmonary Mortality After Transplantation
MicroRNAs as Diagnostic and Predictive Biomarkers for Acute Graft Versus Host Disease
Safety and Efficacy of UC-MSC in Patients With Acute Severe Graft-versus-host Disease
Mesenchymal Stromal Cells for Acute Graft Versus Host Disease
Biomarkers for Acute Graft-versus-host Disease